Advertising revival and owned-brand momentum lift India’s fashion e-commerce platform, yet profitability puzzle remains only half-solved The monsoon has ended for Nykaa’s advertising business, and investors should be relieved. FSN E-Commerce Ventures,... Read more »
The 25-year-old Mumbai firm sells data and AI services to Fortune 500 companies. Now it wants Rs 2,834 crore from retail and institutional investors to fund its next chapter. Fractal’s business model... Read more »
Mutual funds let small investors access big opportunities. Here’s how they turn your monthly savings into a diversified portfolio Ask some one what a mutual fund is, and you’ll probably hear something... Read more »
A manpower solutions company with 10,374 deployed workers and 25 clients to raise Rs 17 cr PAN HR Solutions Ltd. is in the business of putting people to work — literally. The... Read more »
A specialty chemicals micro-cap with a 66-product portfolio, one factory, and 24 employees goes public on NSE SME Emerge Biopol Chemicals Ltd. traces its roots to United Chemical Company, a specialty chemicals... Read more »
India’s telecom leader posted another strong quarter with ARPU hitting Rs 259 and free cash flow at Rs 194 billion. Bharti Airtel continues executing flawlessly, posting its third consecutive quarter of steady... Read more »
India’s largest two-wheeler maker posted 21% revenue growth while finally gaining traction in scooters and premium bikes. Hero MotoCorp is proving that market leadership doesn’t require standing still. The company that built... Read more »
The country’s largest lender, SBI, is doing well on all fronts State Bank of India just delivered a class in how to navigate a tricky credit environment. While private sector banks grapple... Read more »
The state-owned behemoth is shedding its mass-market legacy for higher-margin products. Life Insurance Corporation of India is pulling off something remarkable: teaching an elephant to dance. The state-owned insurance giant, long synonymous... Read more »
India’s fifth-largest drugmaker is thriving in diabetes and cardiac care while waiting for its infection-treatment business to recover Mankind Pharma is executing a textbook transition from acute to chronic therapies, and the... Read more »